Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides
暂无分享,去创建一个
R F Schinazi | J. Mellors | R. Schinazi | C. K. Chu | D. Liotta | D. Cannon | M. Nguyen | J W Mellors | D C Liotta | R. Lloyd, | R M Lloyd | M H Nguyen | D L Cannon | A McMillan | N Ilksoy | C K Chu | H Z Bazmi | N. Ilksoy | H. Z. Bazmi | A. McMillan | Cannon | D. Liotta | R. Lloyd | Minh H Nguyen | L. Deborah
[1] R F Schinazi,et al. Delayed treatment with combinations of antiviral drugs in mice infected with herpes simplex virus and application of the median effect method of analysis , 1986, Antimicrobial Agents and Chemotherapy.
[2] R. F. Smith,et al. Human Retroviruses and AIDS. A compilation and analysis of nucleic acid and amino acid sequences: I--II; III--V , 1993 .
[3] S D Kemp,et al. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). , 1989, Science.
[4] D. Richman,et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[5] E A Emini,et al. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors , 1991, Journal of virology.
[6] D. Richman,et al. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay , 1990, Antimicrobial Agents and Chemotherapy.
[7] R. Schinazi,et al. Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication. , 1992, The Journal of biological chemistry.
[8] J. Mellors,et al. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. , 1992, Molecular pharmacology.
[9] M A Wainberg,et al. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine , 1992, Journal of virology.
[10] J. Cameron,et al. Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma , 1992, Antimicrobial Agents and Chemotherapy.
[11] Erik De Clercq,et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives , 1990, Nature.
[12] R F Schinazi,et al. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine , 1992, Antimicrobial Agents and Chemotherapy.
[13] S. Hughes,et al. Comparison of inhibitory activities of various antiretroviral agents against particle-derived and recombinant human immunodeficiency virus type 1 reverse transcriptases , 1989, Antimicrobial Agents and Chemotherapy.
[14] R. Schinazi,et al. Insights into HIV chemotherapy. , 1992, AIDS research and human retroviruses.
[15] R. Schinazi,et al. In situ Complexation Directs the Stereochemistry of N‐Glycosylation in the Synthesis of Oxathiolanyl and Dioxolanyl Nucleoside Analogues. , 1992 .
[16] H. McClure,et al. Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rhesus monkeys , 1992, Antimicrobial Agents and Chemotherapy.
[17] L W Frick,et al. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine , 1992, Antimicrobial Agents and Chemotherapy.
[18] J. Mellors,et al. Use of recombinant retroviruses to characterize the activity of antiretroviral compounds , 1991, Journal of virology.
[19] J. Maizel,et al. HIV-1 reverse transcriptase: structure predictions for the polymerase domain. , 1990, AIDS research and human retroviruses.
[20] T. Steitz,et al. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.
[21] L. Resnick,et al. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[22] S D Kemp,et al. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture , 1991, Journal of virology.
[23] P. Boyer,et al. Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1 , 1992, Journal of virology.
[24] B. Larder,et al. Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[25] T. Chou,et al. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.
[26] R. Schinazi,et al. Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[27] R. Schinazi,et al. Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes , 1992, Antimicrobial Agents and Chemotherapy.
[28] Warren Beach,et al. Synthesis of Enantiomerically Pure (2'r,5's)-(-)- (2-(Hydroxymethyl) Oxathiolan-5-Yl) Cytosine as a Potent Antiviral Agent against Hepatitis-B Virus (Hbv) and Human Immunodefic , 1992 .
[29] J. Cameron,et al. The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro , 1992, Antimicrobial Agents and Chemotherapy.